Please provide your email address to receive an email when new articles are posted on . WASHINGTON — Ophthalmologists need to look and listen for the cause of persistent epithelial defects, according ...
Dublin, July 13, 2020 (GLOBE NEWSWIRE) -- The "Persistent Epithelial Defect (PED) - Epidemiology Forecast - 2030" report has been added to ResearchAndMarkets.com's offering. This report delivers an in ...
Credit: Thinkstock. KPI-012 is a topically dosed ophthalmic therapy designed using the Company's human mesenchymal stem cell secretome platform. The Food and Drug Administration (FDA) has granted Fast ...
Please provide your email address to receive an email when new articles are posted on . All eyes that received a single-layer graft and a 24-hour pressure patch showed complete healing. A three-layer ...
KALA BIO completes patient enrollment in CHASE trial, evaluating KPI-012 for treating persistent corneal epithelial defect, with results due Q3 2025. KALA BIO, Inc. announced the completion of patient ...
The speakers will provide a disease overview of PCED, including the unmet need and patient journey, as well as insights into mesenchymal stem cell secretome (MSC-S), KPI-012 and the CHASE clinical ...
SAN DIEGO, August 18, 2023 (Newswire.com) - Amber Ophthalmics, Inc. (Amber), a privately held, clinical stage biopharmaceutical company, announced today that Dr. Mark S. Gorovoy from Gorovoy M.D. Eye ...
ARLINGTON, Mass., April 12, 2023 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization ...
-- Study did not meet primary endpoint of complete healing of PCED at Week 8; secondary endpoints also did not achieve statistical significance -- -- KPI-012 was well-tolerated with no ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback